Protego

Protego Biopharma

This biotechnology company develops small molecule therapies for patients with systemic amyloid diseases and other protein misfolding disorders.

Eidos Therapeutics

This biopharmaceutical company develops acoramidis, a small molecule therapy designed to treat patients suffering from transthyretin amyloidosis by stabilising the transthyretin protein.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Ambagon Therapeutics

The company develops small-molecule stabilisers to modulate protein interactions for the treatment of cancer and other serious diseases.

ATTR

ATTR develops small-molecule stabilisers to treat patients with transthyretin amyloidosis by preventing protein breakdown and subsequent harmful amyloid deposit formation in the body.

Origo Biopharma

This clinical-stage biotechnology company develops small molecule therapies targeting the transforming growth factor beta pathway to treat fibrosis and cancer in healthcare patients.

RougeTx

This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.

Clotprotect Therapeutics

This company develops small molecule anti-fibrinolytic drugs for patients suffering from acute haemorrhage and severe bleeding.